{"disease":{"id":"abdominal-infection","name":"abdominal infection"},"drugs":{"marketed":[{"drug_id":"zavicefta-ceftazidime-avibactam","indication_name":"Complicated intra-abdominal infections (cIAI) caused by certain susceptible bacteria.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zavicefta, Ceftazidime-Avibactam","generic_name":"zavicefta-ceftazidime-avibactam","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Bacterial cell wall synthesis","drug_class":"Cephalosporin antibiotic and beta-lactamase inhibitor combination","quality_score":55,"revenue":"638","mechanism":""},{"drug_id":"technetium-tc-99m-exametazime","indication_name":"Localization of intra-abdominal infection and inflammatory bowel disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceretec","generic_name":"TECHNETIUM TC 99M EXAMETAZIME","company_name":"GE HealthCare","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"cefoxitin-sodium","indication_name":"Intra-abdominal infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFOXITIN SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":21,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1200962","indication_name":"Complicated Intra-abdominal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFEPIME HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Cefepime is a cephalosporin antibacterial drug."},{"drug_id":"relebactam","indication_name":"Complicated Intra-abdominal Infections (cIAI)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Recarbrio","generic_name":"RELEBACTAM","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Renal Dehydropeptidase Inhibitor [EPC]","quality_score":34,"revenue":null,"mechanism":"Recarbrio works by inhibiting the beta-lactamase enzymes produced by certain bacteria, allowing carbapenem antibiotics to effectively target and kill the bacteria."},{"drug_id":"ceftazidime","indication_name":"Intra-abdominal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"ampicillin-sodium","indication_name":"Intra-Abdominal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AMPICILLIN SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl3989564","indication_name":"Intra-abdominal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TOBRAMYCIN SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"piperacillin-and-tazobactam","indication_name":"Intra-abdominal infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Piperacillin And Tazobactam","generic_name":"Piperacillin Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Bacterial cell wall; beta-lactamase enzyme","drug_class":"Penicillin-class antibacterial with beta-lactamase inhibitor","quality_score":64,"revenue":null,"mechanism":"Piperacillin and tazobactam is an antibacterial drug combining a penicillin with a beta-lactamase inhibitor."},{"drug_id":"cefoxitin","indication_name":"Intra-abdominal infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mefoxin In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFOXITIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Escherichia coli","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Citrobacter freundii","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Enterobacter cloacae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Klebsiella oxytoca","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Enterococcus faecalis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Enterococcus faecium","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."}],"pipeline":[],"offLabel":[],"totalMarketed":18,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05423743","title":"INSPIRE Trial for Abdominal Infections","phase":"NA","overall_status":"COMPLETED","enrollment_count":198480,"lead_sponsor_name":"Harvard Pilgrim Health Care","has_results":true},{"nct_id":"NCT07429929","title":"Saudi Emergency Laparotomy Audit","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"King Faisal Specialist Hospital & Research Center","has_results":false},{"nct_id":"NCT03700749","title":"FALCON Trial Testing Measures to Reduce Surgical Site Infection","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":5480,"lead_sponsor_name":"University of Birmingham","has_results":false},{"nct_id":"NCT04094818","title":"TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis","phase":"","overall_status":"COMPLETED","enrollment_count":1441,"lead_sponsor_name":"Inflammatix","has_results":false},{"nct_id":"NCT05148702","title":"EXTENDed Antibiotic Durations Compared to Standard Durations for Patients With Complicated Intra-abdominal Infection.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1166,"lead_sponsor_name":"Sarah Cockayne","has_results":false},{"nct_id":"NCT03678298","title":"Italian Register for the Study of Complicated Intra-Abdominal Infections","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"World Society of Emergency Surgery","has_results":false},{"nct_id":"NCT04233424","title":"D-PLEX 311: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":977,"lead_sponsor_name":"PolyPid Ltd.","has_results":true},{"nct_id":"NCT02993185","title":"Making Healthy Decisions: A Trial Evaluating the \"Your Move\" Teen Pregnancy-prevention Intervention","phase":"NA","overall_status":"COMPLETED","enrollment_count":808,"lead_sponsor_name":"Carnegie Mellon University","has_results":false},{"nct_id":"NCT04411199","title":"D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"PolyPid Ltd.","has_results":false},{"nct_id":"NCT06633718","title":"Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":786,"lead_sponsor_name":"Qilu Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06828874","title":"A Study of Levornidazole Disodium Phosphate for Injection vs. Ornidazole in Treatment of Postoperative Intra-Abdominal Infections Caused by Anaerobic Bacteria","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":696,"lead_sponsor_name":"Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd","has_results":false},{"nct_id":"NCT03358576","title":"Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":674,"lead_sponsor_name":"Iterum Therapeutics, International Limited","has_results":true},{"nct_id":"NCT05733104","title":"A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03744741","title":"HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections: a Multicenter Pilot Study","phase":"","overall_status":"COMPLETED","enrollment_count":585,"lead_sponsor_name":"Inflammatix","has_results":false},{"nct_id":"NCT02784704","title":"Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Tetraphase Pharmaceuticals, Inc","has_results":true},{"nct_id":"NCT06498245","title":"Early Abdominal Wall Prosthesis Infections: Epidemiology, Risk Factors and Factors Linked to Recovery","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"University Hospital, Strasbourg, France","has_results":false},{"nct_id":"NCT01445678","title":"Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":494,"lead_sponsor_name":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT01069900","title":"Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":458,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT03580733","title":"Study Comparing Caspofungin to Placebo for the Treatment of ICU Intra-abdominal Candidiasis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":448,"lead_sponsor_name":"Centre Hospitalier Universitaire, Amiens","has_results":false},{"nct_id":"NCT06304779","title":"The Effect of Continuous Intravenous Infusion of Lidocaine on PPCs and Prognosis in Emergency Surgical Patients With IAI","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":428,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT03329092","title":"A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":422,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT01506271","title":"Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":351,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04903886","title":"Intensive Care Unit Acquired Infections in Patients Colonized With Extended Spectrum Enterobacteriaceae","phase":"","overall_status":"UNKNOWN","enrollment_count":350,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT07172451","title":"Gelaspan vs Crystalloid Therapy in Sepsis","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":318,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT05127109","title":"The PASTDUe Nutrition Ecosystem Project (PASTDUe)","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT05549076","title":"Hellenic Registry for cIAIs (HERCO-II)","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Maximos Frountzas","has_results":false},{"nct_id":"NCT03830333","title":"Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":268,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05487586","title":"Real-World Study of Ceftazidime Avibactam in China","phase":"","overall_status":"TERMINATED","enrollment_count":220,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06682091","title":"Management and Outcome of Mesh Infection After Abdominoplasty in a Tertiary Care Centre","phase":"","overall_status":"COMPLETED","enrollment_count":209,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT00752219","title":"Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":204,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03633123","title":"D-PLEX 310: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":202,"lead_sponsor_name":"PolyPid Ltd.","has_results":true},{"nct_id":"NCT03544203","title":"Multicentre Observational Study on Community Acquired Intraabdominal Infections Management","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nīmes","has_results":false},{"nct_id":"NCT03997929","title":"Peritoneal 1.3-ß-D-glucan for the Diagnosis of Intra-abdominal Candidiasis in Critically Ill Patients (pBDG2)","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT05147870","title":"Outcome After Laparoscopic Surgery for Peptic Ulcer Perforation","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Chang Wei-Jung","has_results":false},{"nct_id":"NCT04612413","title":"A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":148,"lead_sponsor_name":"Enlivex Therapeutics Ltd.","has_results":false},{"nct_id":"NCT03482245","title":"The Role of Circadian Clock Proteins in Innate and Adaptive Immunity","phase":"NA","overall_status":"RECRUITING","enrollment_count":144,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT03815370","title":"A Non-Traumatic Binder for Temporary Abdominal Wall Closure","phase":"NA","overall_status":"UNKNOWN","enrollment_count":140,"lead_sponsor_name":"Unity Health Toronto","has_results":false},{"nct_id":"NCT04214236","title":"CiNPT for Abdominoplasties in Post-bariatric Patients Study","phase":"NA","overall_status":"UNKNOWN","enrollment_count":130,"lead_sponsor_name":"Azienda Ospedaliera, Ospedale Civile di Legnano","has_results":false},{"nct_id":"NCT05905055","title":"P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Meiji Seika Pharma Co., Ltd.","has_results":false},{"nct_id":"NCT06251583","title":"Prevention of Incisional Hernia With Mesh-suture at Umbilical Trocar Site.","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":124,"lead_sponsor_name":"Miguel A ngel Garci-a Urena","has_results":false},{"nct_id":"NCT01147640","title":"Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT01789905","title":"Tygacil Drug Use Investigation","phase":"","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02739997","title":"Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03061500","title":"Prognostic Value of Proadrenomedullin in Intra-abdominal Sepsis","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Instituto de Investigación Hospital Universitario La Paz","has_results":false},{"nct_id":"NCT07268560","title":"Real-World Effectiveness of Aztreonam-Avibactam Against MBL-Producing CRE","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Sir Run Run Shaw Hospital","has_results":false},{"nct_id":"NCT07130799","title":"Innate Immune Response Monitoring Via Monocyte HLA-DR in Severe Intra-abdominal Infections at Risk of Fungal Infection","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT03862378","title":"Prediction of Intra-abdominal Infectious Complication by Drainage Fluid Analysis","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT06838585","title":"Intra-Abdominal Sepsis and Relationship Between Cumulative Fluid Balance and Serum Sodium and Chloride Levels and In-Hospital Mortality","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Clinical Center of Vojvodina","has_results":false},{"nct_id":"NCT06901544","title":"Capillary Leak Index as a Prognostic Indicator for Post-Operative Abdominal Sepsis in Critically Ill Patients","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Ain Shams University","has_results":true},{"nct_id":"NCT03912870","title":"Value of Flow Cytometry in Infectious Point of Care: Feasibility Study","phase":"","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}